Related Experiment Video

Updated: Jul 19, 2026

Flow Cytometric Detection of Newly-formed Breast Cancer Stem Cell-like Cells After Apoptosis Reversal
11:21

Flow Cytometric Detection of Newly-formed Breast Cancer Stem Cell-like Cells After Apoptosis Reversal

Published on: January 26, 2019

Apoptosis in the treatment of cancer: a promise kept?

Xue Wei Meng1, Sun-Hee Lee, Scott H Kaufmann

  • 1Division of Oncology Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.

Current Opinion in Cell Biology
|October 20, 2006
PubMed

Insights

Cancer cells evade apoptosis through blocked cell death pathways. New therapeutic agents are being developed to selectively kill cancer cells or reset their apoptotic threshold for potential cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Death Research

Background:

  • Cancer cells commonly evade programmed cell death (apoptosis).
  • Alterations in cell death signaling pathways enable cancer cells to survive.
  • Understanding these pathways is crucial for developing novel cancer therapies.

Purpose of the Study:

  • To review recent advancements in targeting apoptosis for cancer therapy.
  • To highlight the development and evaluation of novel therapeutic agents.
  • To assess the potential of modulating apoptosis for clinical benefit.

Main Methods:

  • Review of preclinical and clinical trial data.
  • Analysis of research on cancer cell apoptosis evasion mechanisms.
  • Evaluation of therapeutic agents designed to target cell death pathways.

Main Results:

  • Several novel therapeutic agents targeting apoptosis have shown promise.
  • Preclinical and clinical trials indicate potential efficacy.
  • These agents aim to selectively induce cancer cell death or alter their survival threshold.

Conclusions:

  • Modulating apoptosis holds significant therapeutic potential for cancer treatment.
  • Recent studies suggest that targeting cell death pathways is a viable strategy.
  • Clinical application of apoptosis-modulating agents may soon be realized.

More Related Videos

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Related Concept Videos

Apoptosis01:30

Apoptosis

Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size reduction of the tissue.
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...